ZeeCRO Sells Bioanalytical Division

Tuesday, December 29, 2009 07:42 AM

Cary, N.C.-based contract research organization (CRO) ZeeCRO, formerly AAIPharma Services, sold its bioanalytical division to Kansas Venture Capital, Inc., (KVCI) for an undisclosed sum. KCVI plans to grow the bioanalytical business, which is now a new company, KCAS, Inc.

ZeeCRO streamlined operations to focus on its CRO business in October by selling off its pharmaceutical development services business. As part of that sale, the company lost the rights to the AAIPharma name.  According to ZeeCRO’s web site, the CRO continues to offer early- and late-stage development services to global customers. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs